Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version.

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Healthcare Decision-Making

Background:

• The initial South Korean pharmacoeconomic (PE) guidelines were established in 2006 and revised in 2011.
• Previous versions presented interpretation ambiguities and did not fully incorporate advancements in cost-effectiveness and methodology.
• Evolving healthcare landscapes necessitated an update to ensure relevance and accuracy.

Purpose of the Study:

• To review the revision process and outline the significant changes in the third version of South Korea's PE guidelines, published in January 2021.
• To provide stakeholders with a clear understanding of the updated framework for pharmacoeconomic evaluations.
• To enhance the transparency and consistency of healthcare decision-making processes.

Main Methods:

• Comprehensive review of 50 previous PE submissions and international guidelines.
• Analysis of academic literature and relevant research.
• Incorporation of stakeholder feedback through surveys and advisory meetings.

Main Results:

• Shift in analytical perspective from societal to healthcare system.
• Expanded criteria for selecting comparator drugs beyond market share.
• Reduced discount rate from 5% to 4.5%.
• Inclusion of detailed guidance on non-inferiority margin, extrapolation, utility elicitation, and uncertainty.
• New guidelines for treatment switching and co-dependent technologies; deletion of budget impact analysis guidelines.

Conclusions:

• The 2021 PE guidelines offer a more refined and specific framework for pharmacoeconomic evaluations in South Korea.
• The revisions aim to improve the transparency, consistency, and scientific rigor of healthcare reimbursement decisions.
• The updated guidelines reflect current best practices and address previous limitations.